Published in Biotech Business Week, April 11th, 2005
The double-blind, randomized, three-way crossover study is intended to evaluate the nasal deposition of the GelVac powder as well as to assess the safety and determine the nasal retention characteristics of the GelVac system.
The GelVac system incorporates Carrington's proprietary functional pharmaceutical excipient, GelSite polymer. In animal models, it has been shown to confer two critical properties that could improve nasal immune response: mucoadhesiveness and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.